These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17661736)

  • 41. [Lumiracoxib--Prexigem].
    Duh D; Vandevijver A
    J Pharm Belg; 2007; 62(3):95-6. PubMed ID: 17955960
    [No Abstract]   [Full Text] [Related]  

  • 42. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
    Fenton C; Keating GM; Wagstaff AJ
    Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials.
    Silva RC; Riera R; Saconato H
    Sao Paulo Med J; 2011; 129(5):335-45. PubMed ID: 22069133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.
    Sheldon EA; Beaulieu A; Paster Z; Yu S; Rebuli R
    Clin Exp Rheumatol; 2008; 26(4):611-9. PubMed ID: 18799092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
    Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A; Pandhi S; Nixon RM; Guyot P; Karabis A; Moore RA
    Arthritis Res Ther; 2015 Mar; 17(1):66. PubMed ID: 25879879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lumiracoxib, a highly selective COX-2 inhibitor.
    Jeger RV; Greenberg JD; Ramanathan K; Farkouh ME
    Expert Rev Clin Immunol; 2005 May; 1(1):37-45. PubMed ID: 20477653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How to advise aspirin use in patients who need NSAIDs.
    Sopena F; Lanas A
    Curr Pharm Des; 2007; 13(22):2248-60. PubMed ID: 17691998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
    Chan VW; Clark AJ; Davis JC; Wolf RS; Kellstein D; Jayawardene S
    Acta Anaesthesiol Scand; 2005 Nov; 49(10):1491-500. PubMed ID: 16223396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R; Sheldon E; Maldonado-Cocco J; Dutta D; Yu S; Sloan VS
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience.
    Pareek A; Chandanwale AS; Oak J; Jain UK; Kapoor S
    Curr Med Res Opin; 2006 May; 22(5):977-88. PubMed ID: 16709320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ; Beier J; Geusens P; Hasler P; Patel SK; Senftleber I; Gitton X; Moore A; Sloan VS; Poór G
    Arthritis Rheum; 2004 Aug; 51(4):549-57. PubMed ID: 15334426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
    Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma.
    Cheremina O; Brune K; Hinz B
    Biomed Chromatogr; 2006 Oct; 20(10):1033-7. PubMed ID: 16602135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.